HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.

Abstract
Bilateral Renal Cell Carcinoma (RCC) is an uncommon clinical entity, affecting 3%-6% of patients with localized RCC. Sunitinib has proven efficacy in the management of metastatic RCC (mRCC), however, there is very limited evidence of primary tumor response. With the changing treatment paradigm, the role of sunitinib should be extended to the neoadjuvant setting, to downstage locally advanced primary renal tumors, to facilitate nephron-sparing surgery (NSS), and to select responding patients with mRCC for continuation of treatment after cytoreductive nephrectomy. The role of sunitinib in downstaging primary renal tumors to facilitate curative NSS has not been previously reported. We report the case of recurrent renal tumors in a solitary kidney, where neoadjuvant sunitinib downstaged the tumors enough to allow NSS.
AuthorsJawaher Ansari, Alan Doherty, Ian McCafferty, Michael Wallace, Nayneeta Deshmukh, Emilio Porfiri
JournalClinical genitourinary cancer (Clin Genitourin Cancer) Vol. 7 Issue 2 Pg. E39-41 (Aug 2009) ISSN: 1938-0682 [Electronic] United States
PMID19692322 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Renal Cell (drug therapy, surgery)
  • Combined Modality Therapy
  • Female
  • Humans
  • Indoles (therapeutic use)
  • Kidney Neoplasms (drug therapy, surgery)
  • Middle Aged
  • Neoplasm Metastasis
  • Pyrroles (therapeutic use)
  • Renal Dialysis
  • Sunitinib

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: